46. Prognostic Variables for Survival in a Randomized Comparison of Treatments for Prostatic Cancer Source and Contributor D.P. Byar National Cancer Institute 261 These data were obtained from a randomized clinical trial comparing four treatments for patients with prostatic cancer in Stages 3 and 4. Stage 3 represents local extension of the disease without evidence of distant metastasis and Stage 4 represents distant metastasis as evidenced by elevated acid phosphatase, x-ray evidence, or both. The trial was double-blinded and the treatments were placebo pill, 0.2 mg diethylstilbestrol, DES, 1.0 mg of DES, or 5.0 mg of DES, all drugs administered daily by mouth. Patients were not required to remain indefinitely on their assigned treatment, but were allowed to have their treatment changed at the discretion of the physician if signs of tumour progression or symptoms appeared. This provision was required for ethical reasons. Patients were followed according to a standard protocol at 6 month intervals or more frequently if required. The data for 506 patients given in Table 46.1 consist of an identification number, stage of tumour, a code for the treatment to which the patient was assigned, the date of randomization, the total months of follow-up since randomization, an indicator for the survival status or cause of death, and the values of twelve pretreatment covariates. The goal of an analysis should be to compare the treatments with respect to survival of the patients. Since this was a randomized study it would ordinarily not be necessary to adjust for the values of the pretreatment covariates. However, in such studies it is advisable to examine the prognostic significance of the covariates and to confirm that they are balanced across treatment groups. In addition, the analyst should look for important treatment-covariate interactions which might lead to the definition of subsets of patients in which treatment differences were significantly more marked or even reversed. These data have been analyzed at an earlier stage in their collection in Byar and Corle (1977) and have been re-analyzed in their present form in Byar and Green (1980). 262 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER References Byar, D.P. and Corle, D.K. (1977). Selecting optimal treatment in clinical trials using covariate information. Chronic Diseases 30, 445-469. Byar, D.P. and Green, S.B. (1980). The choice of treatment for cancer patients based on covariate information: application to prostate cancer. Bull. Cancer, Paris 67, 477-488. 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER 263 Table 46.1 Prognostic Variables for Survival in a Randomized Comparison of Treatments for Prostatic Cancer * Pretreatment covariates Date S D E Pat on- Mos Surv Age, B B K no. Stage Rx study FU stat yrs Wt PF HX P P G HG SZ SG AP BM 1 3 2 81067 72 0 75 76 0 0 15 9 4 138 2 8 3 0 2 3 2 92167 1 5 54 116 0 0 13 7 3 146 42 7 0 3 3 4 1 1268 40 3 69 102 0 1 14 8 4 134 3 9 3 0 4 3 2 3 1868 20 3 75 94 1 1 14 7 1 176 4 8 9 0 5 3 1 321 68 65 0 67 99 0 0 17 10 0 134 34 8 5 0 6 3 2 61368 24 1 71 98 0 0 19 10 0 151 10 11 6 0 7 3 1 62668 46 2 75 100 0 0 14 10 1 130 13 9 8 0 8 3 1 62768 62 0 73 114 0 1 17 11 4 126 3 9 6 0 9 3 3 731 68 61 0 60 110 0 0 12 8 0 146 4 10 7 0 10 3 3 8 668 60 0 78 107 0 1 13 8 5 130 21 6 4 0 11 3 3 8 768 60 0 77 89 0 0 15 8 0 156 3 8 6 0 12 3 4 91168 59 0 74 105 0 1 18 14 0 136 6 8 4 0 13 3 2 91868 59 0 74 107 0 0 14 9 5 144 6 9 3 0 14 3 1 91868 49 1 55 112 0 1 16 9 4 139 4 9 10 0 15 3 4 10 168 20 3 73 88 0 0 19 10 4 120 15 10 6 0 16 3 4 10 168 3 2 87 81 1 1 17 12 2 134 3 9 4 0 17 3 1 10 2368 58 0 64 90 0 0 14 8 0 162 6 9 7 0 18 3 3 11 468 29 4 79 104 0 0 13 8 1 150 5 8 5 0 19 3 4 4 969 26 2 62 90 0 1 13 8 1 144 2 9 7 0 20 3 4 42369 52 0 74 107 0 0 13 8 4 164 10 9 7 0 21 3 4 42369 20 2 83 72 1 1 13 9 4 150 1 10 7 0 22 3 3 52169 51 0 65 113 0 0 16 10 0 141 21 9 7 0 23 3 1 52669 51 0 61 97 0 0 11 8 0 135 8 8 6 0 24 4 4 82367 31 1 56 95 0 0 15 10 2 148 26 13 357 1 25 4 3 10 267 42 3 73 103 0 0 16 10 0 146 6 11 39 0 26 4 2 11 1 67 38 2 69 75 0 0 16 8 4 107 25 11 62 0 27 4 1 11 967 69 0 76 82 0 0 12 8 5 117 12 10 25 0 28 4 1 11 13 67 39 1 71 103 0 0 12 7 0 144 11 11 120 0 29 4 3 11 2467 33 5 66 126 0 0 17 10 4 140 32 13 242 0 30 4 2 12 567 8 1 76 90 0 0 15 9 4 128 40 13 23 0 31 4 2 12 15 67 13 1 74 77 2 0 16 9 4 105 17 13 3160 1 32 4 4 1 368 33 7 71 150 0 1 16 10 5 150 9 11 19 0 33 4 3 1 11 68 9 1 71 88 0 1 16 9 4 123 38 13 354 0 34 4 1 1 1968 21 1 79 89 0 0 16 9 4 128 26 12 121 0 35 4 4 2 1 68 66 1 75 101 0 0 15 9 0 146 8 14 38 0 36 4 4 2 1 68 5 1 76 86 0 1 16 6 4 82 10 11 992 1 37 4 1 1 1268 27 7 72 93 0 0 16 10 4 130 2 11 13 0 38 4 2 22768 2 2 69 84 0 1 12 8 1 104 15 13 289 1 39 4 2 5 868 20 1 53 99 0 0 12 9 1 142 26 13 56 1 40 4 3 8 768 19 1 76 85 0 0 14 9 4 130 6 11 14 1 41 4 1 82868 60 0 72 95 0 1 17 8 4 136 12 12 23 0 42 4 3 10 768 58 0 76 0 0 15 8 4 128 35 13 300 1 43 4 4 10 968 32 1 82 89 0 0 14 8 0 130 27 13 223 1 44 4 1 3 469 53 0 74 124 0 0 16 8 3 94 26 15 13 0 45 4 3 32669 53 0 75 93 0 0 13 9 2 153 16 13 33 0 264 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER Table 46.1 (cont.) Pretreatment covariates Date S D E Pat on- Mos Surv Age, B B K no. Stage Rx study FU stat yrs Wt PF HX P P G HG SZ SG AP BM 46 4 4 41869 43 1 74 81 0 0 17 10 4 134 28 11 200 1 47 4 2 52669 21 1 60 96 0 0 12 8 0 143 27 13 70 0 48 3 4 62367 30 9 59 116 1 0 12 8 4 152 - 9 7 0 49 3 4 62867 74 0 49 99 0 0 13 7 0 148 14 8 5 0 50 3 1 81167 72 0 74 96 1 1 11 6 5 104 20 11 6 0 51 3 1 12 15 67 14 1 73 101 0 0 16 7 0 124 18 11 6 0 52 3 4 31468 33 2 76 98 0 1 17 10 5 171 13 8 5 0 53 3 2 32068 8 3 72 84 0 1 12 8 4 148 15 8 6 0 54 3 3 410 68 10 2 73 82 0 1 16 8 4 141 20 9 5 0 55 3 1 41168 51 1 78 108 2 1 18 8 5 148 24 9 3 0 56 3 2 5 668 7 2 71 112 0 1 15 9 0 132 14 11 4 0 57 3 3 51768 63 0 75 92 0 0 13 8 4 152 41 8 0 58 3 2 10 24 68 33 1 64 130 0 0 13 9 0 142 23 11 2 0 59 3 2 3 169 3 3 78 118 0 1 16 9 4 124 3 9 4 0 60 3 1 32969 43 5 60 99 0 0 12 9 0 136 7 9 6 0 61 4 3 6 567 37 1 68 104 0 0 14 9 4 144 32 13 73 1 62 4 1 10 27 67 5 3 77 93 1 0 21 9 5 129 24 13 117 0 63 4 2 10 27 67 6 1 73 102 0 1 14 9 4 120 51 15 87 0 64 4 1 11 367 2 1 70 76 2 0 12 8 0 78 26 11 20 1 65 4 2 3 1 68 5 1 53 106 0 0 14 8 4 143 10 11 7 0 66 4 4 5 1 68 64 0 55 116 0 0 13 9 4 148 26 15 46 1 67 4 4 12 368 1 8 80 91 1 1 14 8 5 117 15 13 13 0 68 4 3 1 11 69 21 1 59 71 0 0 8 4 4 87 27 11 1751 1 69 4 1 22769 16 7 80 111 0 0 16 9 0 113 34 15 11 1 70 3 3 41467 21 3 68 97 1 1 14 8 5 121 18 8 6 0 71 3 3 51067 12 2 77 103 0 1 13 7 2 144 5 9 7 0 72 3 3 51067 75 0 74 110 0 0 16 8 1 136 7 8 5 0 73 3 1 6 767 74 0 70 94 0 0 15 7 1 137 24 7 8 0 74 3 2 6 767 74 0 72 142 1 1 14 13 0 126 - 9 5 0 75 3 2 6 1667 54 1 65 90 0 0 14 8 0 140 47 9 3 0 76 3 4 7 1767 73 0 74 97 0 1 13 7 0 129 6 8 2 0 77 3 1 72667 36 2 72 110 0 1 22 13 5 147 5 10 6 0 78 3 1 72667 59 7 69 97 0 1 13 7 0 143 4 9 3 0 79 3 4 8 467 6 3 72 115 0 1 16 10 0 120 5 8 3 0 80 3 2 82167 58 2 71 87 0 1 13 10 2 134 13 9 8 0 81 3 3 83067 16 6 73 93 0 0 11 7 0 138 8 9 3 0 82 3 4 9 667 19 2 79 106 0 1 16 7 5 136 13 9 2 0 83 3 4 10 10 67 39 2 63 86 0 1 16 8 5 160 7 9 4 0 84 3 2 10 27 67 26 5 74 101 0 1 14 9 2 106 14 8 4 0 85 3 1 10 27 67 60 6 72 118 0 1 17 11 0 156 9 9 6 0 86 3 2 11 267 43 7 78 117 0 1 10 7 4 136 16 8 4 0 87 3 4 12 13 67 7 2 76 92 0 1 12 7 5 136 12 9 5 0 88 3 3 12 13 67 9 5 70 72 0 1 16 9 3 120 17 8 1 0 89 3 3 1 1768 67 0 69 120 0 1 16 10 4 136 21 10 7 0 90 3 4 13068 62 5 76 102 0 1 12 8 0 132 13 8 5 0 91 3 1 5 768 17 6 84 104 0 1 15 10 1 134 8 6 4 0 92 3 2 5 768 25 5 80 98 0 1 15 8 0 123 8 9 5 0 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER 265 Table 46.1 (cont.) Pretreatment covariates Date S D E Pat on- Mos Surv Age, B B K no. Stage Rx study FU stat yrs Wt PF HX P P G HG SZ SG AP BM 93 3 3 61468 000 6 81 97 0 0 10 7 0 134 11 9 7 0 94 3 4 62168 5 2 81 76 0 1 13 7 4 149 28 9 5 0 95 3 4 72468 34 2 71 100 0 1 12 10 4 144 11 6 3 0 96 3 1 9 1768 59 0 77 109 0 0 14 7 0 120 7 10 3 0 97 3 2 10 268 31 2 70 109 0 1 18 8 4 120 28 9 5 0 98 3 1 10 968 58 0 76 108 0 1 12 7 5 120 3 9 3 0 99 3 3 10 21 68 30 3 76 102 0 1 16 9 5 182 52 11 6 0 100 3 2 11 668 57 0 71 97 0 0 13 7 3 134 19 9 6 0 101 3 2 11 13 68 5 2 76 96 0 1 17 8 0 137 33 9 6 0 102 3 4 1 869 55 0 64 100 0 1 16 10 0 137 6 9 2 0 103 3 3 13069 55 0 74 113 0 0 12 7 0 143 7 10 8 0 104 3 1 41769 52 0 76 88 0 1 16 9 0 123 3 8 6 0 105 3 4 42969 000 4 82 82 0 1 13 9 2 116 5 10 6 0 106 3 3 51469 51 0 65 87 0 1 16 8 0 145 2 9 8 0 107 4 2 41467 17 2 70 83 1 0 14 6 0 127 14 11 97 1 108 4 4 41467 70 5 76 92 0 0 13 6 4 97 6 10 62 1 109 4 1 6 767 74 0 77 93 0 0 10 6 1 110 00 12 49 0 110 4 2 61667 74 0 77 99 0 1 17 9 0 128 15 12 24 0 III 4 3 8 1867 20 2 70 103 0 1 12 7 0 135 23 11 102 0 112 4 1 11 767 2 1 73 80 0 1 13 8 4 129 61 12 397 0 113 4 2 1 1568 8 1 63 119 0 1 13 8 4 128 14 15 417 1 114 4 4 21468 27 7 71 91 0 0 13 6 4 120 1 10 12 0 115 4 3 31368 23 3 78 103 1 1 14 8 0 100 38 12 18 1 116 4 1 1 769 1 2 74 100 0 1 13 8 5 144 1 11 11 0 117 4 4 4 469 52 0 70 110 0 1 16 8 5 159 4 10 20 0 118 4 3 5 769 51 0 73 106 0 1 11 8 1 112 10 13 12 1 119 4 4 52069 6 1 74 98 0 1 13 6 2 140 41 12 784 1 120 4 3 52769 000 1 77 91 0 1 12 7 4 143 6 11 17 1 121 4 4 52769 26 2 85 85 0 1 15 7 0 140 12 12 259 0 122 3 1 91467 65 6 72 79 0 1 13 7 0 123 16 9 8 0 123 3 1 91467 52 8 74 106 0 0 14 6 5 138 17 2 0 124 3 2 10 23 67 26 1 78 83 0 0 13 7 0 103 25 11 5 0 125 3 4 10 24 67 70 0 60 110 0 0 14 10 4 143 13 5 0 126 3 1 11 867 6 5 72 76 0 0 11 9 1 100 16 10 7 0 127 3 2 11 867 6 4 68 124 0 0 13 7 2 145 17 9 18 0 128 3 3 12 12 67 68 0 71 93 0 0 15 9 0 145 19 9 3 0 129 3 4 1 368 33 2 65 125 0 0 17 9 5 150 19 8 8 0 130 3 2 2 268 67 0 67 96 0 0 13 7 5 157 7 9 5 0 131 3 2 3 468 58 2 76 94 0 0 12 7 0 142 - 7 3 0 132 3 4 3 868 23 1 74 98 0 0 15 9 3 142 3 12 41 0 133 3 4 4 968 6 5 78 91 0 0 11 7 0 110 4 9 3 0 134 3 3 51068 11 2 74 85 0 0 14 8 1 140 16 9 9 0 135 3 1 6 668 6 1 71 92 0 0 13 7 3 140 9 9 8 0 136 3 3 11 1468 57 0 74 113 0 0 14 7 2 105 20 9 5 0 137 3 3 11 2068 57 0 72 110 0 0 17 10 4 145 20 8 4 0 138 3 1 12469 29 2 57 97 0 0 14 8 4 147 20 9 7 0 266 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER Table 46.1 (cont.) Pretreatment covariates Date S D E Pat on- Mos Surv Age, B B K no. Stage Rx study FU stat yrs Wt PF HX P P G HG SZ SG AP BM 139 3 2 2 769 9 5 74 104 0 0 14 7 0 138 25 8 8 0 140 3 3 32669 53 0 72 105 0 0 12 6 2 136 5 9 7 0 141 3 3 51669 51 0 65 99 0 0 13 8 0 144 10 9 6 0 142 3 4 52169 8 4 83 115 0 0 17 9 4 167 25 9 6 0 143 4 1 731 67 000 7 71 98 2 1 18 9 4 123 34 13 429 1 144 4 4 82267 21 2 73 103 0 0 12 8 0 128 21 11 28 0 145 4 2 11 2967 27 1 71 102 0 0 14 7 0 105 30 13 3670 1 146 4 3 11 2967 22 6 75 124 0 0 18 11 4 156 22 11 70 0 147 4 3 12 567 12 1 71 77 0 0 10 6 2 70 17 13 36 1 148 4 3 12 12 67 68 0 56 69 0 0 13 8 0 107 11 13 14 1 149 4 3 122067 21 7 83 88 0 0 13 7 0 133 15 13 217 0 150 4 2 12 26 67 68 0 71 116 0 0 15 8 4 150 46 10 32 0 151 4 4 12968 000 7 73 98 1 1 15 8 2 102 23 13 1278 0 152 4 4 4 968 2 1 78 74 0 0 12 9 4 140 32 11 47 1 153 4 1 52768 14 1 50 109 0 0 12 8 0 93 17 11 2252 1 154 4 1 62668 18 2 73 101 0 0 16 11 4 140 9 11 27 0 155 4 4 8 1568 5 1 67 111 0 0 12 9 5 96 17 11 70 1 156 4 3 821 68 60 0 72 96 0 0 15 9 0 153 2 15 436 1 157 4 1 82268 40 3 72 96 0 0 14 10 1 105 26 12 299 1 158 4 1 31969 31 1 68 98 0 0 18 10 5 150 - 13 17 0 159 4 2 52069 51 0 78 116 0 0 15 10 4 157 6 13 11 0 160 3 1 12 667 50 9 72 91 0 1 19 9 4 120 16 8 6 0 161 3 2 1 468 46 9 76 118 0 1 18 8 4 145 4 8 7 0 162 3 2 32868 65 0 77 111 0 0 19 9 3 125 20 9 8 0 163 3 4 5 968 9 4 70 127 0 0 13 9 2 118 14 8 2 0 164 3 2 62468 21 5 74 96 0 1 10 7 0 102 18 9 9 0 165 3 2 91668 27 9 71 92 0 1 15 8 5 106 5 8 4 0 166 3 3 22869 54 0 69 89 0 1 12 7 0 135 4 8 5 0 167 3 3 4 769 52 0 70 111 0 1 18 8 2 82 22 9 8 0 168 4 3 5 1567 75 0 58 99 0 0 19 12 4 131 24 11 16 0 169 4 4 5 967 75 0 78 99 0 0 14 7 0 126 27 46 1 170 4 3 7 767 30 2 73 105 0 1 14 6 5 138 9 15 51 0 171 4 4 10 23 67 70 0 69 108 0 0 12 8 0 122 23 11 20 0 172 4 3 11 367 14 5 73 94 0 0 12 7 5 134 31 13 34 0 173 4 1 7 3 68 000 7 73 93 0 0 14 8 0 78 23 15 12 0 174 4 4 7 968 42 2 68 100 0 0 17 10 4 117 32 13 264 0 175 4 3 7 1568 12 2 75 88 0 1 14 6 0 134 31 13 216 1 176 4 1 71968 40 2 68 104 0 1 17 10 5 150 25 10 9 1 177 4 1 72268 2 1 76 88 0 1 16 7 0 112 32 13 262 0 178 4 3 10 30 68 12 1 76 87 1 1 14 5 4 117 28 14 428 1 179 4 2 3 969 53 0 75 89 0 1 14 8 0 126 8 11 20 0 180 4 2 31269 11 1 59 116 0 1 10 6 0 128 6 11 24 0 181 3 4 62767 18 2 72 96 0 0 11 8 0 103 9 11 33 1 182 3 3 9 667 13 3 80 91 0 0 15 8 2 123 4 8 6 0 183 3 2 10 10 67 45 7 78 112 0 1 16 8 0 150 7 9 3 0 184 3 3 10 12 67 8 9 52 90 0 1 13 8 4 148 4 9 3 0 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER 267 Table 46.1 (cont.) Pretreatment covariates Date S D E Pat on- Mos Surv Age, B B K no. Stage Rx study FU stat yrs Wt PF HX P P G HG SZ SG AP BM 185 3 4 122767 28 1 75 87 0 0 9 5 4 127 8 8 10 0 186 3 4 1 468 67 0 67 109 0 1 14 8 0 140 3 9 8 0 187 3 2 1 1668 67 0 74 103 0 0 16 6 4 130 4 9 4 0 188 3 1 12468 24 2 79 107 1 1 23 10 4 116 2 9 2 0 189 3 2 410 68 64 0 73 96 0 0 15 10 2 120 4 9 5 0 190 3 3 42468 26 2 75 113 2 0 12 7 4 135 1 13 7 0 191 4 2 82867 57 1 72 88 0 0 14 7 4 120 7 12 594 0 192 4 2 9 11 67 32 1 55 96 0 1 15 9 4 103 12 11 2 0 193 4 1 91367 71 0 68 1 1 16 9 0 146 18 11 2 0 194 4 2 913 67 42 3 48 100 1 1 14 10 4 123 3 11 15 0 195 4 1 91867 20 2 75 88 0 1 9 5 4 140 1 11 48 0 196 4 3 91967 71 0 56 94 0 0 12 8 0 144 1 10 11 0 197 4 4 41868 54 6 70 86 0 0 14 9 4 144 4 11 12 0 198 4 4 42368 64 0 54 89 0 0 15 6 2 148 8 13 12 1 199 4 4 42368 51 2 87 82 0 0 14 7 0 110 3 15 21 1 200 3 4 5 1567 1 2 73 94 0 1 14 9 4 133 22 8 8 0 201 3 1 6 1 67 2 7 76 94 0 0 16 10 0 107 8 9 6 0 202 3 4 62767 000 1 68 106 0 0 15 9 0 107 69 13 9 0 203 3 1 62767 54 3 70 97 0 1 17 10 2 138 10 9 6 0 204 3 2 11 17 67 69 0 65 83 0 0 12 6 0 160 8 9 6 0 205 3 1 12 467 68 0 79 95 0 0 14 8 4 134 11 9 4 0 206 3 1 110 68 67 0 70 120 0 0 19 11 0 147 7 9 5 0 207 3 3 22668 66 0 70 99 0 0 12 8 0 160 8 9 6 0 208 3 1 410 68 64 0 59 90 0 1 14 8 0 104 2 9 3 0 209 3 2 52368 63 0 72 73 2 0 13 8 0 142 11 8 6 0 210 3 3 61068 35 3 76 88 0 1 14 9 0 152 4 5 6 0 211 3 4 62068 62 0 78 123 0 0 13 8 1 168 00 10 9 0 212 3 3 7 1668 7 7 76 113 0 1 14 6 4 128 3 8 7 0 213 3 4 731 68 35 7 66 87 0 0 14 9 0 143 3 8 4 0 214 3 3 10 2368 24 4 69 91 0 1 16 10 3 150 11 8 3 0 215 3 4 11 2268 57 0 71 88 0 0 16 8 4 154 3 9 5 0 216 3 2 12 31 68 1 5 75 120 0 0 15 7 4 151 4 8 6 0 217 3 2 21269 4 2 74 99 0 1 17 9 2 157 7 7 6 0 218 4 2 52367 74 5 72 103 0 0 15 9 3 165 4 10 10 0 219 4 2 52467 000 1 78 96 2 0 16 9 4 101 54 12 46 1 220 4 2 61667 51 2 71 110 0 0 14 9 5 134 6 10 7 1 221 4 4 71767 36 2 75 101 0 1 16 10 4 110 15 10 16 0 222 4 2 8 267 16 1 73 89 2 0 15 8 4 72 14 11 204 1 223 4 3 10 367 32 1 79 79 2 0 15 7 1 133 16 13 289 1 224 4 4 12 767 68 0 70 92 0 0 16 8 0 135 22 14 27 0 225 4 2 12 15 67 17 1 73 76 0 0 17 8 0 134 50 13 89 0 226 4 1 22168 66 0 75 98 0 1 14 8 0 147 16 13 28 0 227 4 3 31468 65 0 76 83 0 0 12 6 2 114 13 11 5960 1 228 4 1 3 1968 19 1 71 77 1 0 17 7 5 118 61 15 43 1 229 4 3 32268 41 1 76 91 0 0 17 8 0 151 24 11 82 0 230 4 1 4 568 28 2 73 106 0 1 16 9 0 147 11 11 369 0 268 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER Table 46.1 (cont.) Pretreatment covariates Date S D E Pat on- Mos Surv Age, B B K no. Stage Rx study FU stat yrs Wt PF HX P P G HG SZ SG AP BM 231 4 1 41168 000 2 70 80 0 1 10 8 4 122 5 11 43 0 232 4 4 42668 46 1 72 100 0 1 12 7 5 160 62 11 548 1 233 4 4 52468 63 0 74 101 0 0 14 9 5 148 25 10 24 0 234 4 3 8 568 60 0 62 98 0 0 12 8 4 156 15 13 45 0 235 4 3 91968 59 0 53 116 0 0 13 8 0 164 7 12 10 0 236 3 4 5 167 46 2 54 91 0 0 13 10 0 130 15 9 7 0 237 3 3 5 167 63 1 58 94 0 1 16 10 3 138 12 9 2 0 238 3 4 61367 8 2 78 99 0 1 17 9 5 120 9 8 1 0 239 3 3 61567 74 0 77 100 0 1 10 7 3 124 25 9 4 0 240 3 1 62167 18 2 61 152 0 1 15 10 4 141 18 7 2 0 241 3 1 91267 33 7 78 98 1 1 13 7 4 136 9 9 5 0 242 3 1 92567 12 2 68 88 1 1 24 12 4 144 12 9 2 0 243 3 2 92767 1 7 62 76 1 0 10 6 - 116 13 9 3 0 244 3 3 22968 66 0 70 109 0 0 15 10 0 145 15 11 6 0 245 3 3 61768 28 5 75 81 0 0 16 10 0 137 19 10 5 0 246 3 2 9 568 30 2 80 91 0 0 12 8 4 108 22 11 9 0 247 3 2 91868 57 7 76 99 0 1 13 8 5 112 20 8 5 0 248 3 3 92068 50 1 68 102 0 0 16 8 0 120 20 11 7 0 249 3 1 10 18 68 39 2 73 81 0 1 19 4 4 125 18 11 3 0 250 3 1 101868 40 2 79 96 0 0 15 10 4 140 16 6 3 0 251 3 2 4 469 24 3 78 81 0 1 14 7 5 110 4 9 4 0 252 3 4 6 369 6 2 79 94 0 1 11 8 5 122 4 6 4 0 253 4 2 81467 30 2 72 90 1 1 22 12 4 123 15 14 5 1 254 4 2 9 867 58 1 52 106 0 1 11 7 0 150 13 14 53 0 255 4 3 12 1867 68 0 76 97 0 1 15 10 4 146 19 11 3535 0 256 4 2 1 368 24 1 74 85 0 0 16 10 2 100 19 13 139 1 257 4 1 1 1268 33 8 71 86 0 0 14 8 0 102 8 11 4 1 258 4 4 32568 65 0 72 96 0 0 14 10 2 123 17 12 200 0 259 4 4 32568 2 4 77 113 0 0 15 8 0 138 22 12 55 0 260 4 2 41168 64 0 73 100 0 1 16 10 4 138 23 11 97 0 261 4 1 6 468 19 1 75 83 0 0 12 7 2 118 17 13 23 0 262 4 1 10 968 58 0 73 0 0 13 7 5 133 20 13 11 0 263 4 4 31869 15 1 71 98 0 0 15 10 4 147 12 11 431 1 264 4 2 32169 10 1 76 94 0 1 16 9 0 105 20 12 336 0 265 4 4 32169 12 1 49 90 1 0 14 8 4 141 21 15 56 1 266 4 4 32769 53 0 74 91 2 1 13 7 2 134 17 11 2783 1 267 4 3 5 569 51 0 59 97 0 0 13 6 0 141 17 13 22 0 268 4 3 52969 1 2 79 116 0 1 15 9 2 126 23 11 38 0 269 3 3 102067 40 1 78 113 0 0 20 10 - 132 36 11 6 0 270 3 1 2 168 40 1 78 110 0 0 14 8 - 148 15 9 3 0 271 3 3 2 868 66 0 79 96 0 0 14 8 - 148 19 8 4 0 272 3 2 21968 2 4 72 82 0 0 13 7 4 94 33 11 6 0 273 3 2 4 868 21 1 58 136 1 1 14 8 1 105 30 12 7 0 274 3 4 41168 35 1 73 101 0 0 12 6 0 128 46 11 6 0 275 3 1 92368 29 1 75 113 0 1 19 8 5 109 21 11 4 0 276 3 4 12 968 54 1 78 107 0 0 14 9 0 128 42 11 297 0 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER 269 Table 46.1 (cont.) Pretreatment covariates Date S D E Pat on- Mos Surv Age, B B K no. Stage Rx study FU stat yrs Wt PF HX P P G HG SZ SG AP BM 277 3 4 12069 37 2 60 94 0 0 15 9 0 130 10 9 4 0 278 3 2 3 769 10 5 72 83 0 0 11 7 0 138 15 9 4 0 279 4 4 42767 29 1 59 99 3 0 13 8 0 127 17 13 9999 1 280 4 3 92767 71 0 84 107 0 0 14 7 - 130 15 11 379 1 281 4 1 92767 12 1 74 107 0 1 15 8 0 146 18 11 84 0 282 4 2 10 1967 13 1 76 97 0 0 14 8 0 137 36 15 155 0 283 4 1 12 467 27 1 80 135 0 1 11 7 5 129 17 11 38 0 284 4 2 11 867 66 1 72 123 0 1 15 8 2 158 00 13 18 0 285 4 1 22968 28 1 59 100 0 0 14 8 - 158 21 11 53 0 286 4 3 4 368 31 1 74 111 0 0 13 8 0 152 25 13 42 0 287 4 3 521 68 12 1 65 102 0 0 15 9 0 155 19 11 22 0 288 4 1 521 68 9 2 71 119 0 0 19 10 4 136 24 13 256 1 289 4 2 10 17 68 21 1 76 94 0 0 14 6 0 106 24 11 109 1 290 4 4 11 2768 19 1 74 74 3 0 14 5 3 112 2 11 37 1 291 4 3 52369 51 0 75 114 0 0 18 7 5 138 22 11 23 0 292 3 1 4 667 71 1 73 134 1 1 22 10 4 140 22 11 6 0 293 3 3 41267 76 0 74 99 0 1 17 7 0 111 12 11 4 0 294 3 4 42167 46 1 72 112 1 1 16 8 0 130 30 11 6 0 295 3 2 5 567 47 5 75 107 0 1 15 9 4 162 7 9 11 0 296 3 2 5 567 75 0 70 99 1 0 12 7 0 139 7 9 9 0 297 3 4 5 567 75 0 61 94 0 0 12 7 4 120 4 9 8 0 298 3 3 5 567 49 2 71 94 0 1 16 7 4 156 9 9 3 0 299 3 4 51067 75 0 57 84 0 0 12 8 0 139 6 8 5 0 300 3 4 5 1567 75 0 65 111 0 0 14 8 5 137 15 9 8 0 301 3 1 531 67 31 2 78 96 1 1 17 11 0 149 2 10 2 0 302 3 1 6 567 69 1 60 122 0 0 13 9 0 161 26 9 5 0 303 3 2 62367 74 0 72 102 0 0 16 8 0 140 23 7 3 0 304 3 3 71067 25 7 81 102 1 0 15 8 5 128 4 8 5 0 305 3 4 8 1567 72 0 70 87 0 0 15 8 0 146 5 10 3 0 306 3 2 82167 28 7 62 88 0 1 12 7 6 135 10 8 3 0 307 3 3 82567 36 7 68 98 0 0 16 7 2 133 40 9 4 0 308 3 1 831 67 8 1 74 97 0 0 14 8 4 136 14 8 5 0 309 3 2 92867 71 0 65 117 0 1 15 8 0 165 9 9 8 0 310 3 1 10 10 67 60 3 74 95 0 1 18 9 0 98 2 8 7 0 311 3 3 10 30 67 14 4 76 99 0 1 15 9 4 120 9 11 8 0 312 3 2 11 2967 22 7 70 78 0 0 14 7 2 149 9 11 2 0 313 3 4 12 467 67 8 73 105 0 0 13 6 2 149 39 9 5 0 314 3 1 12 15 67 62 2 71 107 0 1 18 10 4 145 9 8 3 0 315 3 4 12 15 67 68 0 73 118 0 0 17 9 3 134 4 9 7 0 316 3 1 122067 68 0 71 108 0 0 16 12 4 141 7 9 4 0 317 3 3 12 22 67 27 3 75 145 0 0 13 8 1 154 4 9 5 0 318 3 2 122967 68 0 70 98 0 0 11 7 4 142 19 10 5 0 319 3 3 122967 68 0 77 98 0 0 12 6 5 155 9 9 4 0 320 3 1 1 468 67 0 71 87 0 0 15 8 0 156 8 8 6 0 321 3 1 1 468 67 0 75 101 0 0 14 7 3 135 18 7 5 0 322 3 2 1 468 3 2 74 105 0 1 16 7 4 141 10 11 3 0 270 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER Table 46.1 (cont.) Pretreatment Covariates Date S D E Pat on- Mos Surv Age, B B K no. Stage Rx study FU stat yrs Wt PF HX P P G HG SZ SG AP BM 323 3 4 1 1568 49 2 72 100 0 0 11 6 4 150 8 11 3 0 324 3 4 1 1668 12 6 89 92 0 1 13 6 5 136 8 9 7 0 325 3 2 1 1668 30 6 75 96 0 0 12 6 4 143 10 12 7 0 326 3 3 12668 67 0 71 101 0 0 14 8 4 147 3 11 5 0 327 3 3 1 31 68 5 5 80 95 0 1 16 10 4 145 7 9 9 0 328 3 3 21268 65 5 51 96 0 0 13 8 0 118 2 6 6 0 329 3 1 21368 24 7 71 81 0 0 9 4 0 137 10 9 4 0 330 3 2 21968 66 0 72 95 0 1 10 5 0 140 8 8 7 0 331 3 4 22268 36 2 70 91 0 1 16 9 3 159 7 9 10 0 332 3 1 22668 66 0 55 103 0 0 16 10 5 167 2 8 8 0 333 3 2 22668 40 3 76 104 0 1 15 7 4 146 3 9 5 0 334 3 2 22668 13 7 68 97 0 0 17 9 4 95 11 8 5 0 335 3 4 32068 40 3 75 81 0 1 12 8 5 155 14 8 4 0 336 3 2 32668 65 0 52 101 0 1 15 10 4 140 4 6 0 337 3 2 4 168 000 7 75 91 0 0 20 10 4 118 3 11 2 0 338 3 3 411 68 14 2 75 94 0 1 11 7 4 175 15 9 8 0 339 3 3 41168 45 3 72 77 0 0 13 7 0 110 4 8 5 0 340 3 3 41168 64 0 74 118 0 0 14 8 0 142 4 6 6 0 341 3 3 41168 13 6 75 91 0 0 13 7 2 121 5 8 5 0 342 3 1 41868 24 5 75 79 0 1 13 9 5 109 8 8 4 0 343 3 1 5 668 15 2 71 96 0 1 12 8 4 173 5 11 8 0 344 3 1 5 968 26 2 76 102 0 1 15 9 4 112 10 8 5 0 345 3 3 5 968 5 1 70 83 0 0 14 7 5 117 33 13 3 0 346 3 2 5 13 68 63 0 73 129 0 1 21 11 4 167 10 8 7 0 347 3 4 7 868 35 2 70 107 0 1 13 8 5 161 7 11 8 0 348 3 1 7 868 61 0 75 93 0 0 13 8 0 137 10 12 1 0 349 3 4 71968 61 0 70 127 0 0 14 7 0 162 8 9 6 0 350 3 4 72468 50 9 74 97 0 1 13 7 0 123 1 8 4 0 351 3 4 731 68 57 2 72 109 0 0 16 10 0 175 8 9 7 0 352 3 4 8 668 21 3 62 109 0 1 16 8 4 164 15 9 7 0 353 3 1 8 668 26 1 72 111 0 0 14 8 0 153 37 11 5 0 354 3 1 8 668 11 6 77 74 0 0 12 6 2 124 45 11 5 0 355 3 3 92368 59 0 52 90 0 0 12 7 4 119 5 8 5 0 356 3 1 92568 42 1 57 89 0 0 12 6 0 139 24 12 5 0 357 3 3 93068 27 3 80 90 0 1 14 8 4 143 9 8 6 0 358 3 2 11 2768 50 2 62 85 0 1 11 7 0 137 6 9 3 0 359 3 3 11 27 68 57 0 72 101 0 0 13 8 0 146 8 10 5 0 360 3 3 11 2768 57 0 72 116 0 0 14 8 4 152 11 9 8 0 361 3 1 12 1668 000 2 77 91 0 1 14 10 5 145 5 9 5 0 362 3 2 12 1968 1 2 72 134 0 1 15 8 4 148 23 9 7 0 363 3 3 22869 54 0 73 100 0 0 18 10 5 117 8 9 7 0 364 3 2 31269 53 1 74 98 0 1 16 8 5 138 11 8 10 0 365 3 2 3 13 69 23 2 74 82 0 1 17 4 5 109 8 8 4 0 366 3 4 32469 8 2 72 110 0 0 15 8 0 131 4 9 8 0 367 3 4 32869 51 4 76 85 0 1 14 8 5 159 25 9 9 0 368 3 1 4 369 27 7 78 111 0 1 15 7 4 123 7 9 5 0 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER 271 Table 46.1 (cont.) Pretreatment Covariates Date S D E Pat on- Mos Surv Age, B B K no. Stage Rx study FU stat yrs Wt PF HX P P G HG SZ SG AP BM 369 3 4 4 769 52 0 83 88 0 1 16 8 5 100 1 7 6 0 370 3 2 42569 52 0 80 99 0 1 13 7 4 130 6 9 5 0 371 3 4 43069 52 0 76 90 0 0 15 8 3 133 52 13 4 0 372 3 1 43069 45 3 79 126 0 0 13 8 5 154 7 11 7 0 373 3 2 51669 48 7 76 116 0 1 13 8 4 169 2 9 4 0 374 3 1 52069 18 1 71 110 0 1 14 8 4 130 7 11 3 0 375 4 1 4 667 2 7 61 95 0 0 12 8 4 115 37 12 256 1 376 4 4 42467 2 2 77 96 1 1 14 7 4 119 36 10 9 1 377 4 3 51067 35 3 76 82 0 0 10 6 4 103 10 13 93 1 378 4 3 51967 75 0 71 106 0 0 15 8 0 141 26 13 100 0 379 4 1 531 67 75 0 77 87 0 0 11 6 1 125 5 11 22 0 380 4 1 62267 9 4 78 89 0 1 18 8 2 143 39 13 253 1 381 4 3 8 467 39 1 58 92 0 0 12 8 4 137 5 11 108 1 382 4 4 8 467 000 2 74 113 0 1 11 8 4 142 41 13 23 0 383 4 1 10 667 26 3 75 116 0 1 18 9 2 160 26 11 5 1 384 4 1 10 25 67 17 4 62 102 0 0 18 11 5 146 16 13 101 0 385 4 2 11 2767 43 6 80 92 0 0 15 9 4 131 00 13 11 0 386 4 4 12 467 53 1 61 79 1 0 13 8 0 103 14 11 40 0 387 4 3 122967 47 3 76 98 0 1 17 9 5 134 19 11 38 0 388 4 2 32868 11 1 79 99 1 0 16 8 4 91 38 13 314 1 389 4 2 32868 65 0 66 116 0 0 12 8 0 149 18 12 581 0 390 4 3 32968 16 1 61 83 0 1 12 6 2 136 4 15 385 1 391 4 4 32968 21 8 79 99 0 0 17 9 4 161 4 13 61 0 392 4 2 42368 64 0 70 99 0 1 13 7 0 142 11 11 11 0 393 4 2 7 868 7 1 73 105 0 1 15 7 3 156 10 9 11 0 394 4 4 7 1268 38 1 72 90 0 0 11 8 4 148 11 15 15 0 395 4 3 62468 55 1 81 98 0 1 13 6 0 112 38 12 87 1 396 4 1 62468 5 6 77 92 0 0 15 9 4 115 6 10 6 0 397 4 2 8 968 28 1 76 76 0 0 11 6 4 148 29 13 18 0 398 4 1 81668 38 1 75 113 0 1 10 6 2 133 9 13 4 1 399 4 2 81668 20 1 72 79 0 0 14 7 0 122 24 11 72 1 400 4 4 821 68 24 1 74 108 0 0 16 9 0 126 12 13 11 0 401 4 4 82368 27 1 70 85 0 0 16 8 2 164 9 13 18 0 402 4 3 93068 31 1 61 91 0 1 14 8 1 107 25 13 1522 1 403 4 1 10 168 9 1 77 116 0 1 14 8 2 152 7 13 470 0 404 4 3 10 968 9 1 60 73 0 0 11 8 - 141 46 13 170 1 405 4 3 11 1268 11 8 72 86 1 0 12 7 2 140 50 15 11 0 406 4 4 11 2768 56 1 64 104 0 0 17 7 0 120 43 13 24 1 407 4 1 12 568 36 1 78 95 0 0 15 9 4 138 55 10 32 0 408 4 2 12 1668 56 0 74 108 0 1 14 8 5 106 4 15 11 0 409 4 4 12 16 68 15 5 73 83 0 1 12 7 4 112 00 11 42 0 410 4 4 52269 51 0 71 104 0 0 15 7 3 160 26 11 8 1 411 3 1 92567 33 3 75 113 0 1 17 9 4 138 9 9 7 0 412 3 3 10 967 70 0 72 105 0 0 13 8 0 138 3 9 8 0 413 3 4 12 567 32 2 68 89 0 1 19 10 4 138 3 9 6 0 414 3 3 21368 5 5 74 91 0 0 15 8 0 151 3 9 4 0 272 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER Table 46.1 (cont.) Pretreatment Covariates Date S D E Pat on- Mos Surv Age, B B K no. Stage Rx study FU stat yrs Wt PF HX P P G HG SZ SG AP BM 415 3 4 31968 23 2 72 93 0 1 16 8 4 166 4 9 2 0 416 3 1 51468 63 0 79 110 0 0 15 9 5 169 2 9 7 0 417 3 2 6 568 30 1 62 104 0 1 12 8 4 160 32 11 4 0 418 3 2 610 68 12 1 69 92 0 1 17 7 5 155 22 9 0 419 3 1 71068 53 2 62 119 0 0 19 11 4 164 14 9 5 0 420 3 1 91168 12 2 72 128 0 0 15 8 4 164 15 9 6 0 421 3 1 10 868 58 0 72 109 0 0 13 8 4 133 12 9 6 0 422 3 3 2 469 54 0 51 112 0 0 13 9 0 158 7 8 8 0 423 3 1 21969 36 1 72 104 0 0 18 10 0 164 4 9 6 0 424 3 2 31869 20 6 81 104 0 0 15 8 0 169 16 13 8 0 425 4 4 6 767 74 0 71 81 0 0 11 7 5 131 29 11 118 0 426 4 1 61967 34 1 77 103 0 0 14 7 2 143 35 11 13 0 427 4 2 10 367 70 0 73 114 0 1 14 8 0 147 26 11 5 0 428 4 1 22168 25 1 56 100 0 0 17 8 4 138 30 11 506 1 429 4 2 3 668 65 0 77 107 0 0 14 9 4 147 1 13 16 0 430 4 1 41068 4 1 78 104 0 0 16 9 3 127 27 11 226 0 431 4 3 71668 10 1 76 96 0 0 12 7 5 138 34 11 360 1 432 4 3 10 1068 58 0 68 79 0 0 18 9 2 134 9 11 12 0 433 4 1 10 28 68 37 1 73 90 0 0 14 9 1 94 21 13 51 0 434 4 4 1223 68 56 0 56 135 0 0 16 9 0 147 10 10 32 0 435 4 3 41569 6 1 74 112 0 1 20 10 4 131 9 11 213 1 436 3 4 61367 54 1 76 84 0 1 15 8 0 126 19 - 4 0 437 3 4 91467 000 2 69 113 0 1 13 8 0 113 1 9 1 0 438 3 3 10 24 67 70 0 73 84 0 1 10 6 1 156 1 9 5 0 439 3 3 103067 70 0 71 105 0 0 12 8 0 136 2 10 2 0 440 3 2 11 15 67 28 2 75 97 0 1 14 8 5 108 2 9 2 0 441 3 3 122767 40 2 69 85 0 0 15 7 5 59 2 9 3 0 442 3 3 1 2268 67 0 73 95 0 0 11 7 0 138 7 8 4 0 443 3 2 6 368 36 6 59 81 0 0 15 10 0 160 2 9 4 0 444 3 1 6 368 23 6 68 93 0 0 13 7 0 125 2 8 9 0 445 3 1 6 368 23 2 78 115 0 1 14 7 3 130 2 8 1 0 446 3 1 6 368 62 0 63 95 0 0 12 9 0 132 3 8 3 0 447 3 2 61468 62 0 74 85 0 0 12 9 3 141 2 9 4 0 448 3 1 62768 62 0 72 103 0 0 16 7 4 143 00 5 4 0 449 3 4 8 668 2 2 78 103 0 0 11 7 5 112 00 6 6 0 450 3 2 9 568 34 1 70 85 0 0 14 9 1 149 2 12 6 0 451 3 3 101068 4 2 72 101 0 0 14 10 2 164 1 9 8 0 452 3 2 10 18 68 12 1 76 103 0 1 13 7 5 125 4 8 5 0 453 3 1 12 468 56 0 66 106 0 0 12 9 5 155 4 9 5 0 454 3 4 12 1968 1 2 88 99 0 1 13 6 5 141 17 9 7 0 455 3 4 5 669 7 7 78 88 0 1 11 6 5 109 5 9 3 0 456 4 1 7 367 4 1 79 105 0 0 12 7 0 122 5 12 30 0 457 4 1 10 12 67 70 0 77 106 0 1 15 8 2 160 1 9 22 0 458 4 4 32568 65 0 71 101 0 0 12 7 0 127 2 10 15 0 459 4 2 62768 7 1 74 91 0 1 15 8 0 126 8 13 113 0 460 4 3 72968 30 2 75 124 0 0 15 10 2 132 3 13 17 0 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER 273 Table 46.1 (cont.) Pretreatment Covariates Date S D E Pat on- Mos Surv Age, B B K no. Stage Rx study FU stat yrs Wt PF HX P P G HG SZ SG AP BM 461 4 2 91168 40 2 77 90 0 1 10 6 3 147 2 12 82 0 462 4 1 12 1968 13 2 75 74 0 1 15 9 0 158 4 11 11 0 463 4 2 21469 22 1 64 110 0 0 16 10 2 93 6 11 63 1 464 4 3 21469 000 2 79 89 0 0 17 10 3 103 19 13 20 1 465 4 1 32169 18 1 60 134 2 1 16 8 5 141 9 13 12 0 466 3 2 9 767 64 9 70 107 0 0 14 9 4 141 8 9 2 0 467 3 4 10 27 67 13 2 73 111 0 1 15 8 4 170 4 9 7 0 468 3 1 12 867 26 1 61 109 0 0 14 9 2 143 3 11 4 0 469 3 4 1 2268 1 4 79 97 1 1 16 8 4 136 3 9 6 0 470 3 1 3 468 16 2 78 88 0 0 12 7 - 114 4 9 4 0 471 3 3 10 368 38 7 66 1 9 11 9 472 3 2 12 11 68 33 2 72 106 0 13 8 5 165 17 11 6 0 473 3 3 2 1869 14 6 76 - 29 9 12 9 474 3 1 2 1869 16 2 76 90 0 0 13 8 2 120 5 11 0 475 3 1 32069 53 0 76 6 9 476 4 2 52267 22 1 51 100 0 0 16 9 0 146 5 13 6 0 477 4 2 6 667 30 1 59 87 0 1 15 9 0 151 32 13 30 0 478 4 4 72467 53 3 73 91 0 1 16 9 2 146 4 10 32 0 479 4 2 9 767 53 1 74 90 0 1 13 7 2 118 5 13 13 0 480 4 1 9 767 7 1 77 93 2 1 14 9 5 118 43 11 430 1 481 4 2 10 1267 61 1 74 95 0 0 15 7 2 135 5 11 244 0 482 4 1 10 2367 40 1 60 125 0 0 11 7 0 140 9 11 13 0 483 4 1 1 2268 9 2 72 83 0 1 14 8 2 129 18 13 14 1 484 4 3 321 68 14 1 79 88 0 1 12 7 5 86 20 14 0 485 4 3 9 468 59 0 50 117 0 0 12 8 0 153 - 13 103 0 486 4 3 92768 59 0 73 71 0 0 16 8 0 134 3 11 7 1 487 4 4 10 25 68 7 2 72 110 0 0 14 6 0 137 4 11 21 0 488 4 2 121168 56 0 60 - 11 140 9 489 4 4 52869 12 1 80 105 2 1 14 7 5 85 6 5 1600 1 490 4 4 62769 46 3 69 71 1 1 11 8 5 137 5 13 14 1 491 4 3 62769 50 0 75 116 0 0 14 8 0 160 1 11 45 0 492 4 4 62769 000 4 71 99 1 1 14 8 3 141 1 11 17 0 493 3 4 410 69 52 0 73 114 0 1 14 8 4 136 8 8 5 0 494 3 3 43069 19 5 76 99 0 1 15 9 3 160 7 9 2 0 495 3 1 43069 52 0 73 114 0 0 15 7 0 117 5 9 3 0 496 3 3 6 269 51 0 76 114 0 1 30 18 4 116 6 9 5 0 497 3 4 6 269 51 0 68 98 0 0 14 8 0 134 6 9 7 0 498 4 2 41869 14 1 64 100 1 0 14 7 0 140 23 11 6 0 499 4 2 52369 27 1 75 102 0 0 16 8 0 142 5 11 296 0 500 4 3 52269 51 0 60 123 0 1 14 10 4 145 6 8 5 1 501 4 4 52669 5 2 73 100 0 1 19 10 0 168 2 11 29 0 502 3 3 110 69 000 5 78 108 0 0 11 6 0 158 9 13 6 0 503 3 2 3 369 41 8 78 127 0 1 16 10 4 158 5 9 5 0 504 3 3 31169 53 0 77 93 0 0 17 10 3 160 11 9 8 0 505 4 4 12469 19 1 82 96 0 1 12 6 4 124 32 13 84 0 506 4 3 52169 4 1 74 97 1 0 15 6 0 212 33 222 1 274 46. COMPARISON OF TREATMENTS FOR PROSTATIC CANCER ~:Treatment: Date on-study: Mos FU: Survival Status: Age: Wt: PF: HX: SBP: DBP: EKG: HG: SZ: SG: AP: BM: denotes unknown value 1, placebo 2, 0.2 mg. estrogen 3, 1.0 mg. estrogen 4, 5.0 mg. estrogen Date of randomization given as month-day-year Complete months of follow-up Survival status at last visit: 0, alive 1, dead from prostatic cancer 2, dead from heart or vascular disease 3, dead from cerebrovascular accident 4, dead from pulmonary embolus 5, dead from other cancer 6, dead from respiratory disease 7, dead from other specific non-cancer cause 8, dead from unspecified non-cancer cause 9, dead from unknown cause 89 denotes 89 years or more - denotes age unknown Weight index: Weight in kg. - Height in cm. + 200 Performance Rating: 0, normal activity 1, in bed less than 50% of daytime 2, in bed more than 50% of daytime 3, confined to bed History of cardiovascular disease: 0, no; 1, yes Systolic blood pressure: only hundreds and tens digits are recorded, ego 95 coded as 9, 122 coded as 12 Diastolic blood pressure: coding same as SBP Electrocardiogram code: 0, normal 1, benign 2, rhythmic disturbances and electrolyte changes 3, heart blocks or conduction defects 4, heart strain 5, old myocardial infarct 6, recent myocardial infarct Serum haemogoblin in g/lOO ml.: coded as a percentage with one implied decimal place. eg., 13.8 coded as 138 Size of primary tumour estimated in cm2 from rectal examination: 00, no palpable tumour Combined index of tumour stage and histologic grade Serum prostatic acid phosphatase in KingArmstrong units: Coded with one implied decimal place Bone metastases: 0, no; 1, yes